CompletedPhase 1

Use of Ravicti™ in Patients With MCAD Deficiency With the 985A>G (K304E) Mutation

United States4 participantsStarted 2013-06

Plain-language summary

This is a medical research study to test a medication in adult patients with a disease called medium-chain acyl-CoA dehydrogenase (MCAD) deficiency caused by at least one copy of the 985A\>G mutation. The medication is glycerol phenylbutyrate, called Ravicti, which is currently FDA approved for the treatment of urea cycle disorders. Previous research suggests that Ravicti may also be effective in the treatment MCAD deficiency. This study will investigate the safety and efficacy (how well it works) of Ravicti in patients with MCAD deficiency caused by having at least one copy of the 985A\>G mutation.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * confirmation of a diagnosis of MCAD deficiency * at least one copy of 985A\>G MCAD mutation * ability to follow protocol Exclusion Criteria: * positive pregnancy test * currently breastfeeding * currently taking any medication for which there is a potential drug interaction with Ravicti, includes corticosteroids, valproic acid, haloperidol, and probenecid * liver or kidney insufficiency

What they're measuring

Metabolic Stress

Timeframe: 7 weeks

Trial details

NCT IDNCT01881984

SponsorUniversity of Pittsburgh

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-02

Results submitted2017-02-14

View on ClinicalTrials.gov More Medium-chain Acyl-CoA Dehydrogenase (MCAD) Deficiency trials